Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Antithrombin-Independent Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Generation in Human Plasma Via Inhibition of Thrombin-Thrombomodulin-Protein C System.

Yoshiyuki Morishima, PhD, Taketoshi Furugohri, Yoko Shiozaki, Nobutoshi Sugiyama, PhD, Toshiro Shibano, PhD

Blood (2006) 108 (11): 914.

https://doi.org/10.1182/blood.V108.11.914.914

Published: 2006

Journal Articles

Impact of Antithrombin Deficiency on Efficacies of DU-176b, a Novel Orally Active Direct Factor Xa Inhibitor, and Antithrombin Dependent Anticoagulants, Fondaparinux and Heparin.

Toshio Fukuda, Yuko Honda, Chikako Matsumoto, Nobutoshi Sugiyama, PhD, Tadashi Matsushita, PhD, Masamitsu Yanada, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD

Blood (2005) 106 (11): 1874.

https://doi.org/10.1182/blood.V106.11.1874.1874

Published: 2005

Journal Articles

In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.

Yoshiyuki Morishima, PhD, Taketoshi Furugohri, Koji Isobe, Yuko Honda, Chikako Matsumoto, Yoko Shiozaki, Sumie Muramatsu, Nobutoshi Sugiyama, PhD, Toshiro Shibano, PhD

Blood (2004) 104 (11): 1862.

https://doi.org/10.1182/blood.V104.11.1862.1862

Published: 2004

Journal Articles

Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.

Taketoshi Furugohri, Yuko Honda, Chikako Matsumoto, Koji Isobe, Nobutoshi Sugiyama, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD

Blood (2004) 104 (11): 1851.

https://doi.org/10.1182/blood.V104.11.1851.1851

Published: 2004

Journal Articles

Antithrombotic Properties of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor in Rat Models of Arterial and Venous Thrombosis: Comparison with Fondaparinux, an Antithrombin Dependent Factor Xa Inhibitor.

Toshio Fukuda, Chikako Matsumoto, Yuko Honda, Nobutoshi Sugiyama, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD

Blood (2004) 104 (11): 1852.

https://doi.org/10.1182/blood.V104.11.1852.1852

Published: 2004

NARROW

Antithrombin-Independent Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Generation in Human Plasma Via Inhibition of Thrombin-Thrombomodulin-Protein C System.

Impact of Antithrombin Deficiency on Efficacies of DU-176b, a Novel Orally Active Direct Factor Xa Inhibitor, and Antithrombin Dependent Anticoagulants, Fondaparinux and Heparin.

In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.

Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.

Antithrombotic Properties of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor in Rat Models of Arterial and Venous Thrombosis: Comparison with Fondaparinux, an Antithrombin Dependent Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Antithrombin-Independent Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Generation in Human Plasma Via Inhibition of Thrombin-Thrombomodulin-Protein C System.

Impact of Antithrombin Deficiency on Efficacies of DU-176b, a Novel Orally Active Direct Factor Xa Inhibitor, and Antithrombin Dependent Anticoagulants, Fondaparinux and Heparin.

In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.

Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.

Antithrombotic Properties of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor in Rat Models of Arterial and Venous Thrombosis: Comparison with Fondaparinux, an Antithrombin Dependent Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only